Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2018 Mar 30

PMID 29594970

Citations 12

Authors

Freddy Caldera

Sumona Saha

Arnold Wald

Christine A Garmoe

Sue McCrone

Bryant Megna

Dana Ley

Mark Reichelderfer

Mary S Hayney

Affiliations

Soon will be listed here.

Abstract

Background: Patients with inflammatory bowel disease (IBD) are often immunosuppressed, and those patients receiving anti-tumor necrosis factor α (TNF) therapy can have lower antibody responses to vaccines. Pertussis cases are at their highest levels in the post-vaccine era. There is little data regarding responses to the Tdap (tetanus, diphtheria, and acellular pertussis) vaccine in IBD patients.

Aims: The aim of this study was to compare sustained vaccine-induced Tdap antibody concentrations in a cohort of IBD patients stratified by medication regimens with healthy controls (HC) who had received an adult Tdap booster.

Methods: We performed a cross-sectional study evaluating antibody responses to Tdap vaccine among IBD patients compared to HC. Our study consisted of three patient groups: adults with IBD stratified by maintenance medication regimen: (1) thiopurine monotherapy; (2) anti-TNF monotherapy; and (3) combination therapy (anti-TNF and immunomodulator (thiopurine or methotrexate)).

Results: Ninety IBD patients and 20 HC participated. Pertussis pertactin antibody concentrations were significantly lower in IBD patients (p = 0.021) compared to HC, and those on anti-TNF agents (monotherapy or combination) had lower antibody concentrations compared to those on thiopurine monotherapy (p = 0.028). Diphtheria antibody concentrations were also lower in IBD patients (p < 0.001), and those on anti-TNF agents (monotherapy or combination) had lower antibody concentrations compared to the thiopurine monotherapy group (p < 0.001).

Conclusion: IBD patients on anti-TNF agents had lower antibody concentrations to diphtheria and pertussis. These findings suggest a need for different Tdap booster schedules for IBD patients on anti-TNF therapy. Clinical Trials Registry NCT02434133.

Citing Articles

High Rates of Seroprotection to Hepatitis B After a Hepatitis B Challenge Dose in Previously Vaccinated Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy.

Ley D, Lazarus S, Forati A, Farraye F, Smith R, Hayney M Dig Dis Sci. 2024; 69(8):3051-3060.

PMID: 38907090 DOI: 10.1007/s10620-024-08527-1.

Vaccination strategies for Korean patients with inflammatory bowel disease.

Lee Y, Kim E Korean J Intern Med. 2022; 37(5):920-930.

PMID: 35934888 PMC: 9449215. DOI: 10.3904/kjim.2022.149.

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.

Friedman M, Curtis J, Winthrop K Ann Rheum Dis. 2021; 80(10):1255-1265.

PMID: 34493491 PMC: 8494475. DOI: 10.1136/annrheumdis-2021-221244.

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.

Jones J, Tse F, Carroll M, deBruyn J, McNeil S, Pham-Huy A J Can Assoc Gastroenterol. 2021; 4(4):e72-e91.

PMID: 34476339 PMC: 8407486. DOI: 10.1093/jcag/gwab016.

A comprehensive review of vaccination in patients with inflammatory bowel diseases: An Indian perspective.

Shah B, Goenka M Indian J Gastroenterol. 2020; 39(4):321-330.

PMID: 32844299 PMC: 7447584. DOI: 10.1007/s12664-020-01069-0.

References

Dominicus R, Galtier F, Richard P, Baudin M . Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a.... Vaccine. 2014; 32(31):3942-9. DOI: 10.1016/j.vaccine.2014.05.034. View

Dezfoli S, Horton H, Thepyasuwan N, Berel D, Targan S, Vasiliauskas E . Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(8):1754-60. DOI: 10.1097/MIB.0000000000000448. View

Wagner K, White J, Andrews N, Borrow R, Stanford E, Newton E . Immunity to tetanus and diphtheria in the UK in 2009. Vaccine. 2012; 30(49):7111-7. DOI: 10.1016/j.vaccine.2012.09.029. View

Dotan I, Werner L, Vigodman S, Agarwal S, Pfeffer J, Horowitz N . Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2011; 18(2):261-8. PMC: 3919517. DOI: 10.1002/ibd.21688. View

Rohde K, Cunningham K, Henriquez K, Nielsen A, Worzella S, Hayney M . A cross-sectional study of tetanus and diphtheria antibody concentrations post vaccination among lung transplant patients compared with healthy individuals. Transpl Infect Dis. 2014; 16(6):871-7. DOI: 10.1111/tid.12288. View

Plotkin S . Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17(7):1055-65. PMC: 2897268. DOI: 10.1128/CVI.00131-10. View

Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J . California pertussis epidemic, 2010. J Pediatr. 2012; 161(6):1091-6. DOI: 10.1016/j.jpeds.2012.05.041. View

Schwartz K, Kwong J, Deeks S, Campitelli M, Jamieson F, Marchand-Austin A . Effectiveness of pertussis vaccination and duration of immunity. CMAJ. 2016; 188(16):E399-E406. PMC: 5088088. DOI: 10.1503/cmaj.160193. View

Kantsone I, Lucenko I, Perevoscikovs J . More than 20 years after re-emerging in the 1990s, diphtheria remains a public health problem in Latvia. Euro Surveill. 2016; 21(48). PMC: 5388112. DOI: 10.2807/1560-7917.ES.2016.21.48.30414. View

10.

Weston W, Friedland L, Wu X, Howe B . Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials. Vaccine. 2012; 30(9):1721-8. DOI: 10.1016/j.vaccine.2011.12.055. View

11.

Krugliak Cleveland N, Rodriquez D, Wichman A, Pan I, Melmed G, Rubin D . Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016; 61(10):2972-2976. DOI: 10.1007/s10620-016-4275-2. View

12.

Storsaeter J, Hallander H, Gustafsson L, Olin P . Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998; 16(20):1907-16. DOI: 10.1016/s0264-410x(98)00227-8. View

13.

Marshall G, Pool V, Greenberg D, Johnson D, Sheng X, Decker M . Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. Clin Vaccine Immunol. 2014; 21(11):1560-4. PMC: 4248760. DOI: 10.1128/CVI.00474-14. View

14.

Rahier J, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y . Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8(6):443-68. DOI: 10.1016/j.crohns.2013.12.013. View

15.

Hodder S, Cherry J, MORTIMER Jr E, Ford A, Gornbein J, Papp K . Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis. 2000; 31(1):7-14. DOI: 10.1086/313913. View

16.

Kim D, Riley L, Harriman K, Hunter P, Bridges C, Woods L . Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017. Ann Intern Med. 2017; 166(3):209-219. DOI: 10.7326/M16-2936. View

17.

Cullen G, Bader C, Korzenik J, Sands B . Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2011; 61(3):385-91. DOI: 10.1136/gutjnl-2011-300256. View

18.

John T, Voysey M, Yu L, McCarthy N, Baudin M, Richard P . Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK.... Vaccine. 2015; 33(36):4579-85. DOI: 10.1016/j.vaccine.2015.06.105. View

19.

. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-7):1-25. View

20.

Acosta A, DeBolt C, Tasslimi A, Lewis M, Stewart L, Misegades L . Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015; 135(6):981-9. PMC: 5736389. DOI: 10.1542/peds.2014-3358. View